European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes


Gale, EAM; Bingley, PJ; Knip, M; Emmett, CL; Swankie, H; Fewell, S; Kearsey, P; Schober, E; Gorus, FK; Dupre, J; Mahon, JL; Profozic, V; Reimers, JI; Mandrup-Poulsen, T; Levy-Marchal, C; Jaeger, C; Bartsocas, C; Vazeou, A; Gyorko, M; Soltesz, G; Madacsy, L; Pastore, MR; Pozzilli, P; Dahl-Jorgensen, K; Joner, G; Kinalska, I; Mrozikiewicz, A; Vaykhonsky, Y; de Leiva, A; Martinez-Larrad, MT; Mauricio, D; Serrano-Rios, M; Ludvigsson, J; Schoenle, EJ; Yilmaz, MT; Carson, DJ; Tennet, H; Robertson, K; Gillespie, KM; Gillmor, H; Moore, WPT; Norcross, A; Williams, AJK; Dinesen, B; Kjellberg, S; Akelsen, HE; Thorsby, E; Undlien, DE; Collier, T; Hardy, P; Sharpe, S; Pocock, S; Ollier, S; Ollier, D; Keynes, M; Drash, AL; Aagenes, O; Dahlquist, G; Laupacis, A; McLean, AEM; Nerup, J; Weber, B; (2004) European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet, 363 (9413). pp. 925-931. ISSN 0140-6736 DOI: https://doi.org/10.1016/S0140-6736(04)15786-3

Full text not available from this repository.

Abstract

Background Results of studies in animals and human beings suggest that type 1 diabetes is preventable. Nicotinamide prevents autoimmune diabetes in animal models, possibly through inhibition of the DNA repair enzyme poly-ADP-ribose polymerase and prevention of beta-cell NAD depletion. We aimed to assess whether high dose nicotinamide prevents or delays clinical onset of diabetes in people with a first-degree family history of type 1 diabetes. Method We did a randomised double-blind placebo-controlled trial of nicotinamide in 552 relatives with confirmed islet cell antibody (ICA) levels of 20 Juvenile Diabetes Federation (JDF) units or more, and a non-diabetic oral glucose tolerance test. Participants were recruited from 18 European countries, Canada, and the USA, and were randomly allocated oral modified release nicotinamide (1.2 g/m(2)) or placebo for 5 years. Random allocation was done with a pseudorandom number generator and we used size balanced blocks of four and stratified by age and national group. Primary outcome was development of diabetes, as defined by WHO criteria. Analysis was done on an intention-to-treat basis. Findings There was no difference in the development of diabetes between the treatment groups. Of 159 participants who developed diabetes in the course of the trial, 82 were taking nicotinamide and 77 were on placebo. The unadjusted hazard ratio for development of diabetes was 1.07 (95% Cl 0.78-1.45; p=0.69), and the hazard ratio adjusted for age-at-entry, baseline glucose tolerance, and number of islet autoantibodies detected was 1.01 (0.73-1.38; p=0.97). Of 168 (30.4%) participants who withdrew from the trial, 83 were on placebo. The number of serious adverse events did not differ between treatment groups. Nicotinamide treatment did not affect growth in children or first-phase insulin secretion. Interpretation Large-scale controlled trials of interventions designed to prevent the onset of type 1 diabetes are feasible, but nicotinamide was ineffective at the dose we used.

Item Type: Article
Keywords: Islet-cell antibodies, dose nicotinamide, insulin-response, autoantibodies, prevention, relatives, mellitus, risk, iddm, progression
Faculty and Department: Faculty of Epidemiology and Population Health > Dept of Medical Statistics
PubMed ID: 15043959
Web of Science ID: 220308600008
URI: http://researchonline.lshtm.ac.uk/id/eprint/14869

Statistics


Download activity - last 12 months
Downloads since deposit
0Downloads
0Hits
Accesses by country - last 12 months
Accesses by referrer - last 12 months
Impact and interest
Additional statistics for this record are available via IRStats2

Actions (login required)

Edit Item Edit Item